---
title: "Obefazimod (ABX464) in Ulcerative colitis: Corticosteroids"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Corticosteroids. Topics: Recommendations for corticosteroid induction and against corticosteroid maintenance: ACG 2025 guideline, Efficacy of systemic corticosteroids and budesonide MMX: ACG 2025 guideline, Recommendations for oral prednisolone and colonic-release corticosteroids: ECCO 2026 guideline, Indication and induction efficacy of budesonide extended-release tablets, and 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/corticosteroids"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Corticosteroids

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Corticosteroids

<a id="topic-2.2.2.1.2-1"></a>

### Recommendations for corticosteroid induction and against corticosteroid maintenance: ACG 2025 guideline

> “21. In patients with moderately active UC, we recommend oral budesonide MMX for induction of remission (Strong recommendation, moderate quality of evidence).”
> “22. In patients with moderately to severely active UC of any extent, we recommend oral systemic corticosteroids to induce remission (Strong recommendation, low quality of evidence).”
> “35. In patients with prior moderately to severely active UC, we recommend against systemic corticosteroids for maintenance of remission (Strong recommendation, moderate quality of evidence).”
> “34. Budesonide MMX has not been studied for maintenance of remission of prior moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.2-2"></a>

### Efficacy of systemic corticosteroids and budesonide MMX: ACG 2025 guideline

> “In a meta-analysis of trials in patients with active UC, the use of systemic glucocorticoids compared with placebo demonstrated a benefit favoring steroids (RR of failure to achieve remission = 0.65; 95% CI 0.45–0.93) (141,164).”
> “A multicenter phase III RCT showed similar results, with significantly more patients treated with budesonide MMX 9 mg (but not 6 mg) achieving combined clinical and endoscopic remission at week 8 compared with placebo (OR = 4.49; 95% CI 1.47–13.72; P = 0.0047) (163).”
> “Although corticosteroids are efficacious in inducing remission in patients with active UC, they should not be used for maintenance of remission and should be tapered instead (158–160). While the optimal tapering regimen has not been determined, the dose is usually reduced over 8–12 weeks (157).”
> “A patient with UC who needs corticosteroids (as opposed to the one who is prescribed them with 5-ASA and without allowing the 5-ASA to be tried as monotherapy) should be treated with therapies approved for moderately to severely active UC and that have demonstrated steroid-sparing effects.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.2-3"></a>

### Recommendations for oral prednisolone and colonic-release corticosteroids: ECCO 2026 guideline

> “We recommend short-term oral prednisolone for induction of remission in non-hospitalized patients with moderate-to-severe ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest treatment with colonic-release corticosteroids for induction of remission in patients with mild-to-moderate ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “Therefore, we performed a meta-analysis of just these two studies and calculated an RR of 2.83 [95% CI: 1.79–4.46] for the induction of clinical remission”
> “Although the optimal dose and regimen for systemic corticosteroids in UC is uncertain, a 40 mg/day dose is typically used and this recommendation is based on an outpatient study where 40 mg/day was more effective than 20 mg/day.”
> “It is essential to administer corticosteroids only for short-term use. The dose should typically be tapered over 6–8 weeks.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.2-4"></a>

### Indication and induction efficacy of budesonide extended-release tablets

> “UCERIS (budesonide) is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.”
> “The primary endpoint was induction of remission after 8 weeks of treatment.”

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Induction of remission in Studies 1 and 2 of budesonide extended-release tablets

| Treatment group | Study 1 n/N (%) | Study 2 n/N (%) |
| --- | --- | --- |
| Budesonide 9 mg | “22/123 (17.9)” | “19/109 (17.4)” |
| Budesonide 6 mg | “16/121 (13.2)” | “9/109 (8.3)” |
| Placebo | “9/121 (7.4)” | “4/89 (4.5)” |

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### Warnings and precautions for budesonide extended-release tablets

> “Systemic effects such as hypercorticism and adrenal suppression may occur with use corticosteroids, including UCERIS.”
> “Glucocorticosteroids, including UCERIS, can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress.”

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

### Complications of chronic corticosteroid use in US adults with ulcerative colitis

> “Patients with long-term or chronic use of CS may present with both short- and long-term complications including infection, hypertension, new-onset diabetes mellitus, osteoporosis, cataracts, and glaucoma.5,6”
> “Although CS therapy is efficacious in inducing remission among most patients with UC, more than 90% of patients will experience an adverse event, and CS dependence is common.4,8,9”
> “The prevalence of several CS-related complications among targeted treatment initiators was significantly higher in chronic CS users compared with nonchronic CS users, with proportions of 55.5% vs 52.4% for patients with infection, leading to an odds ratio (OR) of 1.14 (95% CI = 1.00-1.29; P = 0.0500); 14.5% vs 7.4% for bone loss, leading to an OR of 2.13 (95% CI = 1.72-2.64; P < 0.001); 5.6% vs 3.0% for venous thromboembolism, leading to an OR of 1.93 (95% CI = 1.39-2.68; P < 0.001); and 2.5% vs 0.3% for adrenocortical insufficiency, leading to an OR of 8.24 (95% CI = 3.50-19.37; P < 0.001; Figure 3).”

Source: [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
